News & Progress
Press Releases
-
February 08, 2021
Palleon Pharmaceuticals Appoints Nikola Trbovic to its Board of Directors -
December 04, 2020
Palleon Pharmaceuticals Appoints Deepa Pakianathan, Ph.D., to its Board of Directors -
September 17, 2020
Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases -
February 12, 2020
Palleon Pharmaceuticals Appoints Li Peng, Ph.D., as Chief Scientific Officer
In the News
-
September 17, 2020
With details on lead sialoglycan degrader in place, Palleon raises $100M series B
BioCentury -
Palleon battalion bags $100M series B for glycan push
BioWorld -
Palleon Pharmaceuticals secures $100m in Series B funding
Pharmaceutical Technology -
Jim Broderick reels in a $100M Series B to explore a ‘new and big’ angle of immune regulation
Endpoints
Publications & Posters
- Poster
HYDRA Platform Development to Investigate Siglec-engaging Tumor Immunosuppressive Glyco-codes
Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 9, 2019, Abstract #P118 - Poster
Blockade of Siglec/Sialoglycan Axis Using EAGLE Technology to Potentiate Anticancer Immunity
Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 8, 2019, Abstract #P273 - Publication
Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment
Cancer Immunology Research. April 23, 2019. - Poster
A Novel Therapeutic Modality of Inhibiting the Glyco-Immune Checkpoint Axis to Treat Cancer
American Association for Cancer Research, April 2019, Poster #LB-109
@Palleon_Pharma • Mar 2, 2021
This month we join in recognizing Autoimmune Disease Awareness Month. Here at Palleon we’re working to provide bett… http://cTkZjSRvsc
@Palleon_Pharma • Feb 25, 2021
The 7th International Conference on Biochemistry and #Glycoscience begins this morning and we’re excited to talk ov… http://wclG4yF0S5